Alcon (NYSE:ALC) Azioni

Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

AEOAmerican,Eagle,Outfitters,Store,In,Shopping,Mall,,Manassas,,Va,,Usa,

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CSCO

MMYT

Sony Group Corporation American Depositary Shares

SONY

Le dinamiche di mercato evidenziano segnali di ripresa, mentre gli investitori monitorano i settori chiave che guidano i rialzi.

Borse USA in leggero rialzo: quali aziende potrebbero influenzare i mercati?

Alcon Inc

ALTERNUS CLEAN ENGY INC A by Alternus Clean Energy, Inc.

Alternus Clean Energy Inc

ALLIANCE INTL EDCATN LSNG by ALLIANCE INTL EDUCATION LEASING HLDGS LTD.

ALTECH CORP KANAGAWA by ALTECH CORP KANAGAWA

Altech Corp

ALLIED CRITICAL METALS by ALLIED CRITICAL METALS INC

ATLANTIC CNTRL ENTRPR LTD by Atlantic Central Enterprise Ltd.

Atlantic Central Enterprises Ltd

Alico Inc

ALCHIP TECHNOLOGS LTD TWD by ALCHIP TECHNOLOGIES LIMITED

Alchip Technologies Ltd

ALIMENTATION COUCHE U/ADR by Alimentation Couche-Tard Inc.

Alimentation Couche-Tard Inc

Alpha Copper Corp Ordinary Shares

Alchemix - United States dollar

Alchemy Investments Acquisition Corp 1 - Class A Ordinary Shares

Alchemy Investments Acquisition Corp 1

Alchemy Investments Acquisition Corp 1 - Units

Alchemy Investments Acquisition Corp 1 - Warrants

Morgan Stanley analyst Patrick Wood maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Equal-Weight and lowers the price target from $90 to $84.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Alcon, Lowers Price Target to $84

<ul>
<li>LumiThera's photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments&#x2A; in early and intermediate dry AMD patients1,2</li>
<li>Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4</li>
<li>Alcon aims to expand PBM office-based treatment in approved markets, underscoring its commitment to people living with retinal diseases</li>
</ul>

Alcon To Acquire LumiThera And Its Photobiomodulation Device For Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration; Amount Not Disclosed

The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) Tryptyr&nbsp;(acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Dry Eye Disease (DED)</a>.
Alcon produces contact lenses, dry eye drops, gels and other related products.
Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to increase natural tear production.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44628020/fda-rejects-aldeyras-reproxalap-for-dry-eye-disease-again-citing-efficacy-concerns" rel="noreferrer noopener">FDA Rejects Aldeyra&#8217;s Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns</a>
DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or <a href="https://www.benzinga.com/pressreleases/25/05/b45657628/alcon-announces-fda-approval-of-tryptyr-acoltremon-ophthalmic-solution-0-003-for-the-treatment-of-" target="_blank" rel="noreferrer noopener">increased tear evaporation</a>. It is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally.
&#8220;Today marks a tremendous milestone for Alcon as Tryptyr becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company,&#8221; said David Endicott, CEO of Alcon.
The approval is supported by two Phase 3 clinical trials evaluating more than 930 patients.
In COMET-2 and COMET-3, up to four times more Tryptyr patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p&lt;0.0001).
Consistent results were observed at all time points through Day 90. Tryptyr demonstrated statistically significant natural tear production as early as Day 1.
Tryptyr is available in easy-to-use, single-dose vials: one drop per eye, two times a day. Alcon expects to launch Tryptyr in the U.S. in the third quarter of 2025.
Other FDA-approved treatments for DED include Alcon&#8217;s Eysuvis and Bausch + Lomb Corp&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) Xiidra.
In April, the FDA issued a Complete Response Letter for&nbsp;Aldeyra Therapeutics, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LADX#NASDAQ">LADX</a>) resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44628020/fda-rejects-aldeyras-reproxalap-for-dry-eye-disease-again-citing-efficacy-concerns" rel="noreferrer noopener">dry eye disease</a>.
In March, Alcon&nbsp;agreed to acquire&nbsp;LENSAR&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>) for&nbsp;$14.00&nbsp;per share in cash for an aggregate implied value of <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44459202/alcon-eyes-surgical-edge-with-lensar-buyout-details" rel="noreferrer noopener">approximately&nbsp;$356 million</a>.
The deal also has an additional non-tradeable contingent value right offering of up to&nbsp;$2.75&nbsp;per share in cash. The transaction represents a total consideration of up to approximately&nbsp;$430 million.
Price Action: ALC stock is up 0.47% at $85.79 at the last check on Thursday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45676090/hormel-foods-q2-earnings-miss-estimates-amid-margin-pressure-softness-in-brazil-and-more" target="_blank" rel="noreferrer noopener">Hormel Foods Q2 Earnings Miss Estimates Amid Margin Pressure, Softness In Brazil And More</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

General

BLCO

LADX

LNSR

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

Alcon Receives FDA Approval For TRYPTYR 0.003% For The Treatment Of The Signs And Symptoms Of Dry Eye Disease

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Shares of Alcon Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) fell sharply in today's pre-market trading as the company posted downbeat results for the first <a href="https://www.benzinga.com/quote/ALC">quarter on Tuesday</a>.
Alcon reported quarterly earnings of 73 cents per share which missed the analyst consensus estimate of 75 cents per share. The company reported quarterly sales of $2.45 billion which missed the analyst consensus estimate of $2.51 billion.
The company lowered its FY2025 earnings guidance, but raised its sales guidance.
Alcon shares dipped 5.5% to $87.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares dipped 16.7% to $6.11 in pre-market trading after Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to sell some of its Aurora Innovation stake in a senior notes offering.</li>
<li>GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares fell 14.1% to $36.86 in pre-market trading after reporting weak quarterly sales.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) dipped 13.8% to $10.96 in pre-market trading after the company guided first-quarter revenue down and withdrew FY25 guidance.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) declined 8.1% to $7.79 in pre-market trading after gaining 8% on Tuesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) dipped 7.5% to $2.33 in pre-market trading after jumping over 12% on Tuesday.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) fell 7% to $9.17 in pre-market trading following first-quarter results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) fell 3.2% to $37.77 in pre-market trading.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) dipped 3.1% to $14.50 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Movers

ALLT

GRAL

UBER

WBTN

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $110 price target.

Reiteration

Needham Reiterates Buy on Alcon, Maintains $110 Price Target

WIIM

Alcon shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance below estimates.

With U.S. stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported quarterly earnings of 21 cents per share on sales of $17.25 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Sony shares fell 0.6% to $24.40 in after-hours trading.</li>
<li>American Eagle Outfitters Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) reported preliminary results for the first quarter and withdrew its full-year guidance. After the market close on Tuesday, American Eagle said in a filing that it expects to report first-quarter revenue of $1.1 billion, representing a decline of 5% year-over-year. American Eagle shares dipped 13.5% to $11.00 in the after-hours trading session.</li>
<li>Analysts are expecting Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) to post quarterly earnings at 92 cents per share on revenue of $14.05 billion. The company will release earnings after the markets close. Cisco shares gained 0.2% to $61.91 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) posted downbeat results for the first quarter on Tuesday. The company lowered its FY2025 earnings guidance, but raised its sales guidance. Alcon shares fell 2.4% to $91.00 in the after-hours trading.</li>
<li>Analysts expect MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) to report quarterly earnings at 30 cents per share on revenue of $255.93 million before the opening bell. MakeMyTrip shares rose 0.2% to $106.75 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) lowers FY2025 Adj EPS guidance from $3.15-$3.25 to $3.05-$3.15 vs $3.20 analyst estimate. Raises FY2025 sales outlook from $10.20 billion-$10.40 billion to $10.40 billion-$10.50 billion vs $10.42 billion estimate.

Guidance

Alcon Lowers FY2025 Adj EPS Guidance from $3.15-$3.25 to $3.05-$3.15 vs $3.20 Est; Raises FY2025 Sales Guidance from $10.20B-$10.40B to $10.40B-$10.50B vs $10.42B Est

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported quarterly earnings of $0.73 per share which missed the analyst consensus estimate of $0.75 by 2.67 percent. This is a 6.41 percent decrease over earnings of $0.78 per share from the same period last year. The company reported quarterly sales of $2.45 billion which missed the analyst consensus estimate of $2.51 billion by 2.46 percent. This is a 0.29 percent increase over sales of $2.44 billion the same period last year.

Earnings Misses

Alcon Q1 Adj. EPS $0.73 Misses $0.75 Estimate, Sales $2.45B Miss $2.51B Estimate

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Alcon will report an earnings per share (EPS) of $0.76. 
Alcon bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 2.41% increase in the share price on the following day.
Here's a look at Alcon's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.71</td>
<td>0.74</td>
<td>0.73</td>
<td>0.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.72</td>
<td>0.81</td>
<td>0.74</td>
<td>0.78</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058466_0.png" alt="eps graph" />
<h3>Market Performance of Alcon's Stock</h3>
Shares of Alcon were trading at $95.75 as of May 09. Over the last 52-week period, shares are up 6.17%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALC/earnings">To track all earnings releases for Alcon visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alcon Earnings Preview

<ul>
<li>Alcon welcomes its shareholders to its third in-person AGM</li>
<li>Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member</li>
<li>Proposed dividend of CHF 0.28 cash per share</li>
</ul>

Alcon Proposes CHF 0.28 Cash Dividend Ahead Of 2025 AGM And Nomination Of New Tech-Focused Board Member

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $108 to $112.

Keybanc Maintains Overweight on Alcon, Raises Price Target to $112

Mizuho analyst Anthony Petrone maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $115 to $120.

Mizuho Maintains Outperform on Alcon, Raises Price Target to $120

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $107 to $110.

Needham Maintains Buy on Alcon, Raises Price Target to $110

Alcon shares are trading higher. The company acquired majority interest in Aurion Biotech.

<ul>
<li>Leverages Alcon's global scale with Aurion's cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025</li>
<li>Aurion's lead asset received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration (FDA)</li>
<li>Positions Alcon at the leading edge of biopharma applications in ophthalmology with the potential to advance the first-ever corneal cell therapy candidate</li>
</ul>

Alcon Acquires Majority Interest in Aurion Biotech; Financial Terms Not Disclosed

<ul>
<li>Clareon Vivity IOL provides an extended range of vision from distance to functional near with a monofocal visual disturbance profile1-3µ‖</li>
<li>Vivity, the world's leading EDOF, is now available on Alcon's Clareon material, providing presbyopia correction with exceptional† clarity and predictable refractive outcomes1,4-7</li>
<li>CE Marked countries will begin commercial rollout of Clareon Vivity and Clareon Vivity Toric from early Q2 2025; also available in AutonoMe automated pre-loaded delivery system in Q3 20258</li>
</ul>

Alcon Secures CE Mark For Clareon Vivity IOL, Bringing Next-Generation Presbyopia Correction To Europe

Shares of eye care company Alcon AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Monday</a>.
The company has agreed to acquire LENSAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNSR#NASDAQ">LNSR</a>), a firm recognized for its laser solutions in cataract surgery.
Under the terms of the deal, Alcon will purchase LENSAR shares for&nbsp;$14.00&nbsp;per share in cash for an aggregate implied value of approximately&nbsp;$356 million. The deal also an additional non-tradeable contingent value right offering up to&nbsp;$2.75&nbsp;per share in cash, conditioned on the achievement of 614,000 cumulative procedures with LENSAR&#8217;s products between January 1, 2026, and December 31, 2027. The transaction represents a total consideration of up to approximately&nbsp;$430 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44456336/james-hardie-acquires-building-products-maker-azek-for-875b-stock-plummets" rel="noreferrer noopener">James Hardie To Acquire AZEK In $8.75 Billion Deal, Expanding Its Grip On Outdoor Living Market</a>
The transaction is set to close by mid-to-late 2025, pending regulatory and shareholder approvals. Alcon held <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43957894/alcon-reports-full-year-2024-results-with-strong-top-line-and-earnings-growth-and-record-cash-gene" rel="noreferrer noopener">$1.7 billion in cash and equivalents </a>as of December 31, 2024.
&#8220;We are excited for the opportunity to bring LENSAR&#8217;s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,&#8221; said Alcon CEO David Endicott.
&#8220;By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.&#8221;
The acquisition will expand Alcon&#8217;s femtosecond laser-assisted cataract surgery (FLACS) offerings by integrating LENSAR&#8217;s ALLY Robotic Cataract Laser System, Streamline software, and additional laser technologies.
The system aims to reduce reliance on blade incisions while improving surgical outcomes, particularly in managing astigmatism and other complex cataract conditions.
Currently, there are more than 5 million cataract procedures in the U.S. and approximately 32 million globally.
Price Action: ALC stock traded higher by 1.91% at $92.29 while LNSR is down 2.40% at $14.47 at last check Monday.
Read Next:<a target="_blank" href="https://www.benzinga.com/25/03/44456578/why-dna-test-provider-23andmes-stock-is-plunging-today" rel="noreferrer noopener"></a>
<ul>
<li><a href="https://www.benzinga.com/25/03/44456578/why-dna-test-provider-23andmes-stock-is-plunging-today" target="_blank" rel="noreferrer noopener">Why Is DNA Test Provider 23andMe Stock Tumbling Today?</a></li>
</ul>
Image via Shutterstock.

Equities

Alcon Eyes Surgical Edge With LENSAR Buyout: Details

Press Releases

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Alcon Publishes Agenda for 2025 Annual General Meeting

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

Alcon Announces Results of 2025 Annual General Meeting

Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

Comments

Alcon

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO